badillodacyroic1505.blogspot.com
Trubion uses a proprietary drug design process to creatwe a novel class of compounds called Small ModularImmunoPharmaceuticals (SMIPs). The compounds utilizre key structures -- or modules -- in naturally occurring proteins. Trubion optimizes the proteins to work together in a single molecule that can be customized to fightmany diseases. Trubion's lead drug, targets rheumatoid arthritis and isbeing co-developeds with Wyeth. A second TRU-016, targets non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Trubion was founded in 2002. Trubion went publidc in 2006, raising $52 million. Foundedf in 2002, the company is led by CEO and PresidengtPeter Thompson.
Trubion reported revenues of $36.5 millioh in 2006
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment